Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3

Jack J Chen; Kumar D Thakur; Michael P Clark; Steven K Laughlin; Kelly M George; Roger G Bookland; Jan R Davis; Edward J Cabrera; Vijay Easwaran; Biswanath De; Y George Zhang

doi:10.1016/j.bmcl.2006.08.022

Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3

Bioorg Med Chem Lett. 2006 Nov 1;16(21):5633-8. doi: 10.1016/j.bmcl.2006.08.022. Epub 2006 Aug 24.

Authors

Jack J Chen¹, Kumar D Thakur, Michael P Clark, Steven K Laughlin, Kelly M George, Roger G Bookland, Jan R Davis, Edward J Cabrera, Vijay Easwaran, Biswanath De, Y George Zhang

Affiliation

¹ Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Rd., Mason, OH 45040, USA. [email protected]

PMID: 16934457
DOI: 10.1016/j.bmcl.2006.08.022

Abstract

A new class of pyrimidine-based Janus tyrosine kinase 3 (JAK3) inhibitors are described. Many of these inhibitors showed low nanomolar activity against JAK3.

MeSH terms

Janus Kinase 3 / antagonists & inhibitors*
Pyrimidines / chemistry*
Pyrimidines / pharmacology*

Substances

Pyrimidines
Janus Kinase 3